91 related articles for article (PubMed ID: 26988879)
1. Validity of mesothelin in occupational medicine practice.
Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
[TBL] [Abstract][Full Text] [Related]
2. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP
J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141
[TBL] [Abstract][Full Text] [Related]
3. DHEA-S, Androstenedione, 17-β-estradiol signature as novel biomarkers for early prediction of risk of malignant pleural mesothelioma linked to asbestos-exposure: A preliminary investigation.
Nuvoli B; Sacconi A; Bottillo G; Sciarra F; Libener R; Maconi A; Carosi M; Piperno G; Mastropasqua E; Papale M; Camera E; Galati R
Biomed Pharmacother; 2024 Jun; 175():116662. PubMed ID: 38692064
[TBL] [Abstract][Full Text] [Related]
4. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
[TBL] [Abstract][Full Text] [Related]
5. Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma.
Fukuoka K; Kuribayashi K; Yamada S; Tamura K; Tabata C; Nakano T
Mol Clin Oncol; 2013 Nov; 1(6):942-948. PubMed ID: 24649274
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
[TBL] [Abstract][Full Text] [Related]
7. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R
Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917
[TBL] [Abstract][Full Text] [Related]
8. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
Tsim S; Alexander L; Kelly C; Shaw A; Hinsley S; Clark S; Evison M; Holme J; Cameron EJ; Sharma D; Wright A; Grundy S; Grieve D; Ionescu A; Breen DP; Paramasivam E; Psallidas I; Mukherjee D; Chetty M; Cox G; Hart-Thomas A; Naseer R; Edwards J; Daneshvar C; Panchal R; Munavvar M; Ostroff R; Alexander L; Hall H; Neilson M; Miller C; McCormick C; Thomson F; Chalmers AJ; Maskell NA; Blyth KG
J Thorac Oncol; 2021 Oct; 16(10):1705-1717. PubMed ID: 34116230
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic biomarker of asbestos-related mesothelioma: example of translational research.
Okio H; Kazu S; Masahiro M
Cancer Sci; 2007 Aug; 98(8):1147-51. PubMed ID: 17532755
[TBL] [Abstract][Full Text] [Related]
10. Asbestos exposure biomarkers in the follow-up of asbestos-exposed workers.
Paolucci V; Romeo R; Sisinni AG; Scancarello G; Volterrani L; Mazzei MA; Barabesi L; Sartorelli P
Ind Health; 2018 Jun; 56(3):249-254. PubMed ID: 29479016
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Hagiwara Y; Hamada Y; Kuwahara M; Maeda M; Segawa T; Ishikawa K; Hino O
Cancer Sci; 2008 Apr; 99(4):666-70. PubMed ID: 18294289
[TBL] [Abstract][Full Text] [Related]
12. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma.
Byun AJ; Grosser RA; Choe JK; Rizk NP; Tang LH; Molena D; Tan KS; Restle D; Cheema W; Zhu A; Gerdes H; Markowitz AJ; Bains MS; Rusch VW; Jones DR; Adusumilli PS
Ann Surg; 2023 Nov; 278(5):e1003-e1010. PubMed ID: 37185875
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin methylation, soluble mesothelin related protein levels and inflammation profiling in workers chronically exposed to naturally occurring asbestos fibers.
Ledda C; Loreto C; Lombardo C; Cardile V; Rapisarda V
Transl Oncol; 2024 Feb; 40():101872. PubMed ID: 38134842
[TBL] [Abstract][Full Text] [Related]
15. Tasks and Experiences of the Prospective, Longitudinal, Multicenter MoMar (Molecular Markers) Study for the Early Detection of Mesothelioma in Individuals Formerly Exposed to Asbestos Using Liquid Biopsies.
Weber DG; Casjens S; Wichert K; Lehnert M; Taeger D; Rihs HP; Brüning T; Johnen G; The MoMar Study Group
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136442
[TBL] [Abstract][Full Text] [Related]
16. Variation rs2235503 C > A Within the Promoter of
Silvestri R; Pucci P; De Santi C; Dell'Anno I; Miglietta S; Corrado A; Nicolí V; Marolda D; Cipollini M; Pellegrino E; Evangelista M; Bonotti A; Foddis R; Cristaudo A; Landi S; Gemignani F
Front Genet; 2020; 11():975. PubMed ID: 33014022
[TBL] [Abstract][Full Text] [Related]
17. Serum Levels of N- and C-ERC/Mesothelin and Clinicopathological Factors in Mesothelioma Patients and Those without Mesothelioma.
Koyanagi AI; Kajino K; Nojiri S; Abe M; Kobayashi T; Sugitani Y; Yue L; Ohtsuji N; Arakawa A; Sato T; Takahashi K; Suzuki K; Orimo A; Yao T; Hino O
Juntendo Iji Zasshi; 2023; 69(2):124-136. PubMed ID: 38854453
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Review of Mesothelioma Cases: From Diagnosis to Therapeutic Strategies.
Qasim A; Allu SVV; Schmidt P; Parikh HR; Moore S; Yapor L; Soliman M
Cureus; 2024 Jan; 16(1):e52859. PubMed ID: 38406142
[TBL] [Abstract][Full Text] [Related]
19. Applications of Neural Network-Based Plan-Cancer Method for Primary Diagnosis of Mesothelioma Cancer.
Kapila D; Panwar S; Raja MKMM; Mondal T; Rafi SM; Singh SP; Kumar B
Biomed Res Int; 2023; 2023():3164166. PubMed ID: 36785667
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.
Tomasetti M; Santarelli L
Cancers (Basel); 2010 Apr; 2(2):523-48. PubMed ID: 24281081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
